# PXD101 in Treating Patients With Acute Myeloid Leukemia

> **NCT00357032** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Recurrent Adult Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** belinostat
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00357032
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-07
- **Final completion:** 2010-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357032, "PXD101 in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00357032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*